Security
Mereo BioPharma Group plc American Depositary Shares · MREO
MREONASDAQotherCurrentCIK 1719714Updated Oct 29, 2026
MREO price & chart
Loading TradingView…
NASDAQ:MREO on TradingView ↗About the company
Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights. Mereo has entered into an exclusive option and license agreement with Sentynl Therapeutics Inc. for the U.S. rights to commercialize alvelestat, while retaining rest of the world rights and will lead the global development. The agreement also grants Sentynl global rights to manufacture alvelestat for AATD-LD. Mereo has partnered with āshibio, Inc., for vantictumab in ADO2. āshibio, Inc. is funding and leading the global development program and Mereo has retained EU and UK commercia…
In the news
MREO DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – MREO ↗
Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MREO ↗
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm ↗
Recent filings
SCHEDULE 13G/A - filed by BANK OF AMERICA CORP /DE/ regarding Mereo BioPharma Group plc
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Items 1.01, 7.01, 9.01
Show 5 more recent filings
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Completion of Acquisition or Disposition of Assets
Items 2.01, 9.01
ARS filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 53,602,000Source | 88,746,000Source | 34,714,000Source | 62,631,000Source | 96,129,000Source | 40,614,000Source | 68,322,000Source | 55,937,000Source | 45,917,000Source | 76,390,000Source | 66,499,000Source | 88,078,000Source |
| Property, Plant and Equipment, NetUSD | 174,000Source | 315,000Source | 54,000Source | 218,000Source | 338,000Source | 91,000Source | 247,000Source | 360,000Source | 137,000Source | 257,000Source | 405,000Source | — |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | 1,089,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 48,698,000Source | 80,522,000Source | 30,118,000Source | 56,125,000Source | 87,431,000Source | 36,223,000Source | 62,483,000Source | 48,660,000Source | 40,992,000Source | 69,802,000Source | 57,421,000Source | — |
| Assets, CurrentUSD | 52,407,000Source | 86,723,000Source | 33,401,000Source | 61,421,000Source | 93,940,000Source | 40,034,000Source | 66,899,000Source | 53,496,000Source | 45,020,000Source | 74,763,000Source | 63,760,000Source | — |
| Prepaid Expense and Other Assets, CurrentUSD | 2,694,000Source | 3,830,000Source | 1,600,000Source | 2,545,000Source | 4,489,000Source | 2,249,000Source | 2,519,000Source | 3,188,000Source | 2,531,000Source | 2,175,000Source | 5,156,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 378,000Source | 909,000Source | 1,003,000Source | 522,000Source | 985,000Source | 108,000Source | 622,000Source | 1,109,000Source | 244,000Source | 727,000Source | 1,245,000Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 7,004,000Source | 16,210,000Source | 6,062,000Source | 8,454,000Source | 17,479,000Source | 6,560,000Source | 8,241,000Source | 13,099,000Source | 5,001,000Source | 15,421,000Source | 15,962,000Source | 26,210,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,134,000Source | 3,051,000Source | 3,145,000Source | 3,132,000Source | 3,032,000Source | 3,145,000Source | 3,132,000Source | 2,775,000Source | 3,135,000Source | 3,059,000Source | 2,775,000Source | — |
| Additional Paid in CapitalUSD | 548,041,000Source | 536,426,000Source | 552,335,000Source | 546,331,000Source | 534,732,000Source | 551,018,000Source | 544,266,000Source | 486,927,000Source | 549,622,000Source | 539,642,000Source | 486,107,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -493,667,000Source | -455,837,000Source | -514,543,000Source | -486,643,000Source | -440,836,000Source | -507,538,000Source | -472,027,000Source | -428,581,000Source | -501,018,000Source | -462,883,000Source | -419,630,000Source | — |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -10,910,000Source | -11,104,000Source | -12,285,000Source | -8,643,000Source | -18,278,000Source | -12,571,000Source | -15,290,000Source | -18,283,000Source | -10,823,000Source | -18,849,000Source | -17,485,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 46,598,000Source | -72,536,000Source | 28,652,000Source | 54,177,000Source | 78,650,000Source | 34,054,000Source | 60,081,000Source | 42,838,000Source | 40,916,000Source | 60,969,000Source | 50,537,000Source | — |
| Liabilities and EquityUSD | 53,602,000Source | 88,746,000Source | 34,714,000Source | 62,631,000Source | 96,129,000Source | 40,614,000Source | 68,322,000Source | 55,937,000Source | 45,917,000Source | 76,390,000Source | 66,499,000Source | — |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,016,000Source | 14,208,000Source | 5,677,000Source | 7,557,000Source | 15,466,000Source | 6,177,000Source | 7,497,000Source | 11,004,000Source | 4,302,000Source | 13,848,000Source | 9,486,000Source | — |
| Operating Lease, Liability, CurrentUSD | 397,000Source | 736,000Source | 1,030,000Source | 601,000Source | 679,000Source | 0Source | 747,000Source | 662,000Source | 202,000Source | 707,000Source | 652,000Source | — |
| Accounts Payable, CurrentUSD | 879,000Source | 1,748,000Source | 1,121,000Source | 1,138,000Source | 2,700,000Source | 3,226,000Source | 2,924,000Source | 2,455,000Source | 1,333,000Source | 2,440,000Source | 2,346,000Source | — |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 394,000Source | 0Source | 0Source | 552,000Source | — | 0Source | 727,000Source | 0Source | 187,000Source | 906,000Source | — |
| Other Liabilities, NoncurrentUSD | 652,000Source | 568,000Source | 370,000Source | 352,000Source | 536,000Source | 362,000Source | 325,000Source | 513,000Source | 661,000Source | 565,000Source | 764,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 4,118,000Source | 3,529,000Source | 2,455,000Source | 5,041,000Source | 3,721,000Source | 2,046,000Source | 2,932,000Source | 2,539,000Source | 2,026,000Source | 4,071,000Source | 5,467,000Source | — |
| CurrentTaxAssetsCurrentGBP | — | — | — | — | — | — | — | — | — | — | — | 1,296,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 32,000Source | 0Source |
| DeferredTaxLiabilityAssetGBP | — | — | — | — | — | — | — | — | — | — | — | -63,344,000Source |
| IntangibleAssetsOtherThanGoodwillGBP | — | — | — | — | — | — | — | — | — | — | — | 24,116,000Source |
| IssuedCapitalGBP | — | — | — | — | — | — | — | — | — | — | — | 1,875,000Source |
| TradeAndOtherCurrentPayablesGBP | — | — | — | — | — | — | — | — | — | — | — | 3,078,000Source |
| Additional Paid in Capital, Common Stock | — | — | — | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,605,000Source | 2,278,000Source | 7,598,000Source | 7,390,000Source | 4,924,000Source | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,957,000Source | 362,000Source | -1,378,000Source | 146,000Source | -1,263,000Source | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -4,312,000Source | -8,329,000Source | -30,971,000Source | -32,834,000Source | -21,132,000Source | — |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -300,000Source | -320,000Source | -20,000Source | -699,000Source | -419,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 20,000Source | 20,000Source | — | 0Source | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 0Source | 422,000Source | 327,000Source | 46,147,000Source | 7,973,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | — | — | — | 12,381,000Source | — | — |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 7,000Source | 7,000Source | 29,000Source | 21,000Source | 884,000Source | — |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | — | 0Source | -1,337,000Source | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -157,000Source | 908,000Source | 1,854,000Source | -233,000Source | 2,818,000Source | — |
| Additional Financial Items | ||||||||||||
| AdjustmentsForFinanceCostsGBP | — | — | — | — | — | — | — | — | — | — | — | 2,910,000Source |
| AdjustmentsForSharebasedPaymentsGBP | — | — | — | — | — | — | — | — | — | — | — | 3,862,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsGBP | — | — | — | — | — | — | — | — | — | — | — | -2,064,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 127,000Source | 106,000Source | 465,000Source | 438,000Source | 395,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | 44,000Source | 38,000Source | 157,000Source | 143,000Source | 171,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | 1,628,000Source | -2,765,000Source | -6,344,000Source | 1,210,000Source | -2,347,000Source | — |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | 196,000Source | -59,000Source | 6,000Source | -101,000Source | 17,000Source | 416,000Source | 805,000Source | -419,000Source | 245,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | — | — |
| General and Administrative ExpenseUSD | — | — | 6,045,000Source | 6,203,000Source | 5,222,000Source | 5,494,000Source | 4,019,000Source | 7,272,000Source | 23,008,000Source | 26,434,000Source | 18,424,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | -532,000Source | — |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesGBP | — | — | — | — | — | — | — | — | — | — | — | 1,529,000Source |
| Investment Income, InterestUSD | — | — | 504,000Source | 983,000Source | 278,000Source | 589,000Source | 327,000Source | 659,000Source | 2,173,000Source | 3,041,000Source | 2,131,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,024,000Source | -15,001,000Source | -7,005,000Source | -14,616,000Source | -6,719,000Source | -12,887,000Source | -41,878,000Source | -43,253,000Source | -29,466,000Source | — |
| Operating Costs and ExpensesUSD | — | — | 200,000Source | 200,000Source | 200,000Source | 200,000Source | 200,000Source | 200,000Source | 700,000Source | 700,000Source | 700,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | — | 0Source | — | — | — | — | 300,000Source | 0Source | -10,000Source | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesGBP | — | — | — | — | — | — | — | — | — | — | — | 937,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | 39,000Source | 47,000,000Source | 11,605,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 0Source | 0Source | 500,000Source | — | — | 500,000Source | 0Source | 10,000,000Source | — |
| Cost of Goods and Services Sold | — | — | — | — | — | — | — | — | — | — | — | —Source |
| Operating Income (Loss)USD | — | — | -10,015,000Source | -9,373,000Source | -7,030,000Source | -10,499,000Source | -8,766,000Source | -11,202,000Source | -40,107,000Source | -47,364,000Source | -28,416,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | — | 0Source | — | — | — | — | 300,000Source | 0Source | -10,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -7,024,000Source | -15,001,000Source | -7,005,000Source | -14,616,000Source | -6,719,000Source | -12,887,000Source | -41,878,000Source | -43,253,000Source | -29,998,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | -532,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,024,000Source | -15,001,000Source | -7,005,000Source | -14,616,000Source | -6,719,000Source | -12,887,000Source | -41,878,000Source | -43,253,000Source | -29,466,000Source | — |
| Earnings Per Share, BasicUSD per share | — | — | -0.01Source | -0.02Source | -0.01Source | -0.02Source | -0.01Source | -0.02Source | -0.05Source | -0.06Source | -0.04Source | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.01Source | -0.02Source | -0.01Source | -0.02Source | -0.01Source | -0.02Source | -0.05Source | -0.06Source | -0.04Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 799,947,013Source | 770,146,589Source | 803,562,708Source | 799,435,329Source | 801,805,570Source | 784,279,387Source | 797,119,632Source | 739,624,264Source | 659,453,921Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 799,947,013Source | 770,146,589Source | 803,562,708Source | 799,435,329Source | 801,805,570Source | 784,279,387Source | 797,119,632Source | 739,624,264Source | 659,453,921Source | — |
| Additional Financial Items | ||||||||||||
| AdministrativeExpenseGBP | — | — | — | — | — | — | — | — | — | — | — | 19,543,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 127,000Source | 106,000Source | 465,000Source | 438,000Source | 395,000Source | — |
| BasicEarningsLossPerShareGBP/shares | — | — | — | — | — | — | — | — | — | — | — | -0.06Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | — | 0Source | 532,000Source | — |
| CurrentTaxExpenseIncomeGBP | — | — | — | — | — | — | — | — | — | — | — | -601,000Source |
| DepreciationRightofuseAssetsGBP | — | — | — | — | — | — | — | — | — | — | — | 583,000Source |
| DilutedEarningsLossPerShareGBP/shares | — | — | — | — | — | — | — | — | — | — | — | -0.06Source |
| EmployeeBenefitsExpenseGBP | — | — | — | — | — | — | — | — | — | — | — | 14,194,000Source |
| ExpenseFromSharebasedPaymentTransactionsWithEmployeesGBP | — | — | — | — | — | — | — | — | — | — | — | 3,862,000Source |
| FinanceCostsGBP | — | — | — | — | — | — | — | — | — | — | — | 3,361,000Source |
| FinanceIncomeGBP | — | — | — | — | — | — | — | — | — | — | — | 696,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | 1,628,000Source | -2,765,000Source | -6,344,000Source | 1,210,000Source | -2,347,000Source | — |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | — | — | 196,000Source | -59,000Source | 6,000Source | -101,000Source | 17,000Source | 416,000Source | 805,000Source | -419,000Source | 245,000Source | — |
| General and Administrative ExpenseUSD | — | — | 6,045,000Source | 6,203,000Source | 5,222,000Source | 5,494,000Source | 4,019,000Source | 7,272,000Source | 23,008,000Source | 26,434,000Source | 18,424,000Source | — |
| Income (Loss) Attributable to Parent, before TaxUSD | — | — | — | — | — | — | — | — | -41,878,000Source | 43,253,000Source | 29,998,000Source | — |
| IncomeTaxExpenseContinuingOperationsGBP | — | — | — | — | — | — | — | — | — | — | — | -1,897,000Source |
| Interest ExpenseUSD | — | — | 28,000Source | 353,000Source | 16,000Source | 24,000Source | 20,000Source | 180,000Source | 255,000Source | 1,370,000Source | 2,881,000Source | — |
| InterestExpenseOnLeaseLiabilitiesGBP | — | — | — | — | — | — | — | — | — | — | — | 209,000Source |
| Interest Income, OperatingUSD | — | — | — | — | — | — | 31,000Source | 0Source | 104,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | 504,000Source | 983,000Source | 278,000Source | 589,000Source | 327,000Source | 659,000Source | 2,173,000Source | 3,041,000Source | 2,131,000Source | — |
| Operating Costs and ExpensesUSD | — | — | 200,000Source | 200,000Source | 200,000Source | 200,000Source | 200,000Source | 200,000Source | 700,000Source | 700,000Source | 700,000Source | — |
| Other IncomeUSD | — | — | — | — | — | — | — | — | 300,000Source | — | — | — |
| OtherOperatingIncomeExpenseGBP | — | — | — | — | — | — | — | — | — | — | — | 811,000Source |
| ProfitLossAttributableToOwnersOfParentGBP | — | — | — | — | — | — | — | — | — | — | — | -34,196,000Source |
| ProfitLossBeforeTaxGBP | — | — | — | — | — | — | — | — | — | — | — | -36,093,000Source |
| ProfitLossFromOperatingActivitiesGBP | — | — | — | — | — | — | — | — | — | — | — | -43,569,000Source |
| Research and Development ExpenseUSD | — | — | 4,270,000Source | 3,170,000Source | 1,808,000Source | 5,373,000Source | 4,747,000Source | 3,930,000Source | 17,766,000Source | 20,930,000Source | 17,418,000Source | 24,962,000Source |
| Other Operating Income | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
Filing attachments
mreo-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 mreo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further update…
Read attachment ↗mreo-ex99_1.htm · 8-K · 2026-08-11
EX-99.1 2 mreo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) • Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease • On option exercise, Sentynl will have the right to commercialize the product in the United States; Mereo to lead global development and…
Read attachment ↗mreo-ex99_1.htm · 8-K/A · 2026-05-12
Exhibit 99.1 Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Highlights London, May 12, 2026 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent corporate developments. “Based on extensive analysis of data across the two global Phase 3 studies of setrusumab in o…
Read attachment ↗mreo-ex99_1.htm · 8-K · 2026-05-12
EX-99.1 2 mreo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Highlights London, May 12, 2026 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for the first quarter ended March 31, 2026, and provided an update on recent corporate developments. “Based on extensive analysis of data across th…
Read attachment ↗mreo-ex99_1.htm · 8-K · 2026-03-19
EX-99.1 2 mreo-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into to mid-2027 London, March 19, 2026 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical compa…
Read attachment ↗mreo-ex99_1.htm · 8-K · 2026-01-12
Exhibit 99.1 Mereo BioPharma Provides Corporate Update Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing to determine potential path forward for the program Cash balance of approximately $41 million as of December 31, 2025; runway guidance updated to mid-2027 London, January 12, 2026 - Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, t…
Read attachment ↗